home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

58.54 -0.89 (-1.50%)

Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

88 89 Next >

3 Hidden Stock Gems That Wall Street Is Overlooking ↗

July 05, 2024

If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three.

Via InvestorPlace

Looking At Bristol-Myers Squibb's Recent Unusual Options Activity ↗

July 02, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 01, 2024

Via Benzinga

What the Options Market Tells Us About Bristol-Myers Squibb ↗

July 01, 2024

Via Benzinga

Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet ↗

June 30, 2024

Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice.

Via InvestorPlace

What the Options Market Tells Us About Bristol-Myers Squibb ↗

June 26, 2024

Via Benzinga

Bristol-Myers Squibb Stock Price Forecast: Is The Downtrend Finally Over? ↗

June 19, 2024

Technical analysis suggests short-term support at $39.90; potential recovery to $56.

Via Talk Markets

This Is What Whales Are Betting On Bristol-Myers Squibb ↗

June 18, 2024

Via Benzinga

Is Bristol Myers Squibb Stock a Buy? ↗

June 28, 2024

Does Bristol Myers have the potential to be a market-beating stock?

Via The Motley Fool

Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma ↗

June 27, 2024

2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on...

Via Benzinga

You’ve Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever. ↗

June 27, 2024

Pharmaceutical stocks can be considered risky, but when their trials get approved by FDA, the stock can go to the moon.

Via InvestorPlace

FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation ↗

June 24, 2024

The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer.

Via Benzinga

7 Dividend Stocks to Buy Now: June 2024 ↗

June 23, 2024

These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands.

Via InvestorPlace

AbbVie Inc. Dividend Stock Analysis - Saturday, June 22 ↗

June 22, 2024

Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend.

Via Talk Markets

S&P 500 Earnings Dashboard 24Q1 - Saturday, June 22 ↗

June 22, 2024

Of the 498 companies in the S&P 500 that have reported earnings to date for 24Q1, 78.7% reported above analyst expectations. This compares to a long-term average of 66%.

Via Talk Markets

Topics Stocks

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

June 22, 2024

You won't need much money to start investing in these great stocks.

Via The Motley Fool

3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold ↗

June 22, 2024

The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields.

Via The Motley Fool

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

June 21, 2024

From Bristol Myers Squibb

Via Business Wire

Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗

June 21, 2024

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.

Via Benzinga

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

June 21, 2024

From Bristol Myers Squibb

Via Business Wire

German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount ↗

June 20, 2024

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

Via Benzinga

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

June 20, 2024

From Bristol Myers Squibb

Via Business Wire

3 Warren Buffett Stocks to Buy Now: June 2024 ↗

June 19, 2024

If you have a long-term view of the market, it’s a good time to look for some Warren Buffett stocks to buy now.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

June 19, 2024

Via Benzinga

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

June 18, 2024

From Bristol Myers Squibb

Via Business Wire

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb ↗

June 18, 2024

These two pharma stocks are beloved by income investors.

Via The Motley Fool

Bristol Myers Squibb Announces Dividend

June 18, 2024

From Bristol Myers Squibb

Via Business Wire

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗

June 17, 2024

With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.

Via InvestorPlace

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

June 17, 2024

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

June 17, 2024

From FN Media Group LLC

Via GlobeNewswire

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

88 89 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com